Research Article
Albumin-Bilirubin Grade as a Novel Predictor of Survival in Advanced Extrahepatic Cholangiocarcinoma
Table 1
Basic characteristics of the included patients.
| Variables | Overall | ALBI grade | 1-2 () | 3 () | |
| Gender (male/female) | 71/38 | 28/19 | 43/19 | 0.289 | Age | 68.9 ± 11.1 | 67.2 ± 11.8 | 70.1 ± 10.4 | 0.155 | Age (≥70/<70 years) | 57/52 | 23/24 | 34/28 | 0.541 | Location (HCCA/DCCA) | 70/39 | 31/16 | 39/23 | 0.742 | CA19-9 (ng/ml) | 534.3 (0.6–2068) | 291.3 (0.6–2068) | 936.2 (0.6–1967) | 0.006 | CEA (ng/ml) | 4.4 (0.9–310.4) | 4.0 (0.9–294.8 | 5.5 (0.9–310.4) | 0.432 | ALT (U/l) | 149 (22–531) | 128 (24–375) | 202 (22–513) | 0.006 | AST (U/l) | 158 (28–541) | 152 (28–541) | 159.5 (35–365) | 0.976 | ALP (U/l) | 553 (39–2556) | 487 (39–2451) | 646.5 (202–2556) | 0.110 | GGT (U/l) | 543 (4.1–2528) | 636 (69–2528) | 492 (4.1–1706) | 0.073 | TBIL (μmol/l) | 249.7 (14.1–706.2) | 161.8 (14.1–325.4) | 306.9 (47.3–706.2) | <0.001 | DBIL (μmol/l) | 201.4 (5.0–649.0) | 146.9 (5.0–299.0) | 261.4 (23–649 | <0.001 | ALB (g/l) | 34.2 (23.6–45.3) | 38.3 (33.1–45.3) | 31.9 (23.6–35.7) | <0.001 | CRP (mg/l) | 16.8 (0.6–205.6) | 11.7 (0.6–111.9) | 28.2 (1.9–205.6) | <0.001 | PLT (109/l) | 237 (54–533) | 240 (117–483) | 237 (54–533) | 0.869 | PT (s) | 11.6 (9.3–16.5) | 10.9 (9.4–12.9) | 12.1 (9.3–16.5) | <0.001 | PT-INR | 1.02 (0.65–16.5) | 0.98 (0.65–12.6) | 1.07 (0.83–16.5) | <0.001 | CP score 5/7/8/9/10 | 1/46/50/10/2 | 1/43/2/0/1 | 0/3/48/10/1 | <0.001 | Outcome (death/no) | 86/23 | 30/17 | 55/7 | 0.002 |
|
|
ALBI: albumin-bilirubin; HCCA: hilar cholangiocarcinoma; DCCA: distal cholangiocarcinoma; CA19-9: carbohydrate antigen 19-9; CEA: carcinoembryonic antigen; ALT: alanine aminotransferase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; GGT: gamma-glutamyl transpeptidase; TBIL: total bilirubin; DBIL: direct bilirubin; CRP: C-reactive protein; PLT: platelet count; ALB: albumin; PT: prothrombin time; PT-INR: prothrombin time-international normalized ratio; CP: Child-Pugh.
|